Device Trial Radar · NCT06122935
Evaluation of the Aurora Xi New Nomogram Software 2.0
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,735
Actual
Start
Nov 27, 2023
Primary completion
Apr 19, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- Fenwal, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical trial to evaluate the safety and effectiveness of the Aurora Xi Plasmapheresis System with a new plasma collection volume nomogram.
Conditions
- Apheresis Related Hypotension
Interventions
Aurora Xi New Nomogram Software 2.0Device
Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
Aurora Xi Currently Approved Software 1.3Device
Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Significant Hypotensive Adverse EventsTime frame: From venipuncture through 72 hours post-donation.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
BioLife Plasma Services
Lakeland, Florida
BioLife Plasma Services
West Des Moines, Iowa
BioLife Plasma Services
American Fork, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.